fda compounding semaglutide warning november 2025 Drugmakers battle pharmacies over compounded Ozempic and Zepbound : Shots FDA warns consumers not to

It is administered exclusively by subcutaneous injection in clinical trials, and no oral formulation has been announced or registered as of April 2026

Patients taking a GLP-1 need to be supported by multidisciplinary care teams that practice strong patient education strategies

Larger amounts of semaglutide will produce greater health benefits but may cause more severe side effects, such as hypoglycemia or gastrointestinal issues in some cases

Retatrutide is being studied for: Type 2 diabetes MASH(Metabolic Dysfunction-Associated Steatohepatitis), a liver condition caused by fat buildup Heart disease risk reduction Knee osteoarthritis in people with higher body weight More research is needed before doctors know whether retatrutide is safe and effective for these conditions

In clinical trials, there were no severe adverse events

The cost of medication is not included in our Testosterone Replacement Therapy (TRT) plan fees